Abstract
Taken in combination, aspirin, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and statins (combination pharmacotherapy) greatly reduce cardiac events. These therapies are underused, even among patients with drug insurance. Out-of-pocket spending is a key barrier to adherence. We estimated the impact of providing combination pharmacotherapy without cost sharing ("full coverage") to insured patients after a myocardial infarction (MI). Under base-case assumptions, compared to standard coverage, three years of full coverage will reduce mortality and reinfarction rates and will save 5,974 per patient. Our analysis suggests that covering combination therapy for such patients will save both lives and money.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adrenergic beta-Antagonists / economics
-
Adrenergic beta-Antagonists / therapeutic use*
-
Aged
-
Aged, 80 and over
-
Angiotensin-Converting Enzyme Inhibitors / economics
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
-
Aspirin / economics
-
Aspirin / therapeutic use*
-
Cost Sharing
-
Cost-Benefit Analysis
-
Drug Therapy, Combination
-
Financing, Personal
-
Heart Failure / drug therapy*
-
Heart Failure / economics
-
Heart Failure / epidemiology
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / economics
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Insurance Coverage*
-
Models, Econometric
-
Myocardial Infarction / drug therapy*
-
Myocardial Infarction / economics
-
Myocardial Infarction / epidemiology
-
Patient Compliance / psychology
-
Patient Compliance / statistics & numerical data*
-
Prescription Fees
-
United States / epidemiology
Substances
-
Adrenergic beta-Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Aspirin